NEW YORK (GenomeWeb) – Swiss startup Scailyte announced yesterday that it has raised CHF 2.8 million (US $2.8 million) in a seed funding round.
The Luzern, Switzerland-based firm will use the capital to improve market entry and to expedite development of ScaiVision, an artificial intelligence-based software that analyzes single-cell data to enhance biomedical research, pharmaceutical discovery, and precision diagnostics.
As part of the funding round, Scailyte has gained Swisscom Ventures as a strategic investor. Zürcher Kantonalbank has also joined the financing round, along with existing shareholders. Dominique Megret, Head of Swisscom Ventures will join Scailyte's board of directors, along with Hemex CEO Pascal Winnen.
"With our AI-based software for single-cell data interpretation, we will accelerate biomedical discovery and enable the next generation of precision diagnostics," Scailyte CEO Peter Nestorov said in a statement. "With the support of strong partners like Swisscom Ventures and Zürcher Kantonalbank, we will grow to become pioneers and leaders in the fast-emerging single-cell analysis market, enabling the clinical application of single-cell data."
Scailyte expects to commercially launch ScaiVision in Q1 2019.